A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have received BCG immunisation 1 month previously.

Trial Profile

A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have received BCG immunisation 1 month previously.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs MVA 85A (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top